Positive News SentimentPositive NewsNASDAQ:ALKS Alkermes (ALKS) Stock Price, News & Analysis → The biggest lie in America unravels… (From Stansberry Research) (Ad) Free ALKS Stock Alerts $24.69 -0.15 (-0.60%) (As of 12:45 PM ET) Add Compare Share Share Today's Range$24.41▼$24.9650-Day Range$23.21▼$26.7352-Week Range$22.01▼$33.71Volume494,507 shsAverage Volume1.84 million shsMarket Capitalization$4.18 billionP/E Ratio9.76Dividend YieldN/APrice Target$36.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Alkermes alerts: Email Address Alkermes MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside49.5% Upside$36.78 Price TargetShort InterestHealthy6.93% of Shares Sold ShortDividend StrengthN/ASustainability-1.17Upright™ Environmental ScoreNews Sentiment1.62Based on 5 Articles This WeekInsider TradingSelling Shares$292,718 Sold Last QuarterProj. Earnings Growth-7.49%From $2.27 to $2.10 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.92 out of 5 starsMedical Sector17th out of 913 stocksPharmaceutical Preparations Industry5th out of 429 stocks 4.3 Analyst's Opinion Consensus RatingAlkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageAlkermes has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alkermes' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.93% of the outstanding shares of Alkermes have been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Alkermes has recently decreased by 9.35%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlkermes does not currently pay a dividend.Dividend GrowthAlkermes does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlkermes has received a 60.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for physical health", "Antipsychotics", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alkermes is -1.17. Previous Next 3.1 News and Social Media Coverage News SentimentAlkermes has a news sentiment score of 1.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Alkermes this week, compared to 6 articles on an average week.MarketBeat Follows3 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alkermes insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $292,718.00 in company stock.Percentage Held by InsidersOnly 4.89% of the stock of Alkermes is held by insiders.Percentage Held by Institutions95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alkermes' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Alkermes are expected to decrease by -7.49% in the coming year, from $2.27 to $2.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alkermes is 9.72, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.82.Price to Earnings Ratio vs. SectorThe P/E ratio of Alkermes is 9.72, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 181.75.Price to Earnings Growth RatioAlkermes has a PEG Ratio of 0.49. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAlkermes has a P/B Ratio of 3.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alkermes' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchThe biggest lie in America unravels…Americans have been fed an insidious lie for decades. Fortunately, it's starting to unravel – and a few powerful investors are starting to take notice. Make no mistake, we're going to be seeing the ripple effects from this story play out for many years to come. I just released video about it. (You'll see why, when you watch it.) About Alkermes Stock (NASDAQ:ALKS)Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Read More ALKS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALKS Stock News HeadlinesJune 4, 2024 | americanbankingnews.comAlkermes (NASDAQ:ALKS) Receives Neutral Rating from HC WainwrightJune 3, 2024 | prnewswire.comAlkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024May 29, 2024 | prnewswire.comAlkermes to Participate in Two Upcoming Investor ConferencesMay 28, 2024 | finanznachrichten.deAlkermes plc: Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024May 28, 2024 | prnewswire.comAlkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024May 25, 2024 | investorplace.com3 Biotech Stocks That Could Be Millionaire-Makers: May EditionMay 23, 2024 | markets.businessinsider.com6 Analysts Assess Alkermes: What You Need To KnowMay 21, 2024 | finance.yahoo.comDo Options Traders Know Something About Alkermes (ALKS) Stock We Don't?May 17, 2024 | seekingalpha.comThe Bottom Fishing Club: Alkermes Has Great Value And SafetyMay 14, 2024 | prnewswire.comAlkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific ConferencesMay 3, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Hold Rating on Alkermes (ALKS)May 2, 2024 | markets.businessinsider.comAlkermes Buy Rating Affirmed on Strong Commercial Performance and Promising Drug PipelineMay 2, 2024 | markets.businessinsider.com7 Analysts Assess Alkermes: What You Need To KnowMay 2, 2024 | markets.businessinsider.comMaintaining Hold on Alkermes Amidst Modest Q1 Performance and Pipeline ProspectsMay 2, 2024 | markets.businessinsider.comAlkermes Hold Rating Justified by Mixed Financial Performance and Uncertain Pipeline ProspectsMay 2, 2024 | prnewswire.comAlkermes plc Completes Sale of Athlone, Ireland Facility to Novo NordiskMay 1, 2024 | investorplace.comALKS Stock Earnings: Alkermes Misses EPS, Misses Revenue for Q1 2024May 1, 2024 | seekingalpha.comAlkermes plc 2024 Q1 - Results - Earnings Call PresentationMay 1, 2024 | markets.businessinsider.comAlkermes plc Q1 Earnings SummaryMay 1, 2024 | prnewswire.comAlkermes plc Reports First Quarter 2024 Financial ResultsApril 30, 2024 | benzinga.comAlkermes Stock (NASDAQ:ALKS), Quotes and News SummaryApril 24, 2024 | finance.yahoo.comAlkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1April 17, 2024 | prnewswire.comAlkermes to Report First Quarter Financial Results on May 1, 2024April 17, 2024 | finance.yahoo.comAlkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 ReleaseApril 12, 2024 | markets.businessinsider.comHold Rating on Alkermes Amid Promising ALKS 2680 Data and Regulatory ChallengesSee More Headlines Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today6/13/2024Next Earnings (Estimated)7/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALKS CUSIPG0176710 CIK1520262 Webwww.alkermes.com Phone(531) 772-8000Fax781-890-0524Employees2,100Year Founded1987Price Target and Rating Average Stock Price Target$36.78 High Stock Price Target$50.00 Low Stock Price Target$25.00 Potential Upside/Downside+49.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$2.53 Trailing P/E Ratio9.74 Forward P/E Ratio10.86 P/E Growth0.49Net Income$355.76 million Net Margins25.17% Pretax Margin27.79% Return on Equity20.31% Return on Assets11.85% Debt Debt-to-Equity Ratio0.23 Current Ratio3.20 Quick Ratio2.77 Sales & Book Value Annual Sales$1.66 billion Price / Sales2.51 Cash Flow$2.31 per share Price / Cash Flow10.66 Book Value$7.21 per share Price / Book3.42Miscellaneous Outstanding Shares169,220,000Free Float160,946,000Market Cap$4.17 billion OptionableOptionable Beta0.47 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Richard F. Pops (Age 62)Chairman & CEO Comp: $2.61MMr. Blair C. Jackson (Age 51)Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO Comp: $1.17MMr. David Joseph Gaffin (Age 52)Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary Comp: $1.15MMr. Iain Michael Brown (Age 55)Senior VP & CFO (Leave of Absence) Comp: $950.88kDr. Craig C. Hopkinson M.D. (Age 56)Executive VP of Research & Development and Chief Medical Officer Comp: $1.24MDr. Floyd E. Bloom M.D. (Age 87)Founder Comp: $57.73kMr. Samuel J. Parisi (Age 49)Interim Principal Accounting Officer & VP of Finance Mr. Thomas HarveyChief Information Officer & Senior VP of ITMs. Sandra CoombsSenior Vice President of Corporate Affairs & Investor RelationsMr. Stephen SchiavoSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsEidos TherapeuticsNASDAQ:EIDXAgios PharmaceuticalsNASDAQ:AGIOPacira BioSciencesNASDAQ:PCRXALX OncologyNASDAQ:ALXOAtea PharmaceuticalsNASDAQ:AVIRView All CompetitorsInsiders & InstitutionsTeachers Retirement System of The State of KentuckyBought 45,903 shares on 5/28/2024Ownership: 0.131%Beck Bode LLCBought 27,272 shares on 5/22/2024Ownership: 0.016%Burney Co.Sold 153,634 shares on 5/22/2024Ownership: 0.014%Tidal Investments LLCBought 16,282 shares on 5/17/2024Ownership: 0.010%Walleye Trading LLCSold 26,300 shares on 5/17/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ALKS Stock Analysis - Frequently Asked Questions Should I buy or sell Alkermes stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALKS shares. View ALKS analyst ratings or view top-rated stocks. What is Alkermes' stock price target for 2024? 10 Wall Street analysts have issued twelve-month target prices for Alkermes' stock. Their ALKS share price targets range from $25.00 to $50.00. On average, they predict the company's stock price to reach $36.78 in the next year. This suggests a possible upside of 49.5% from the stock's current price. View analysts price targets for ALKS or view top-rated stocks among Wall Street analysts. How have ALKS shares performed in 2024? Alkermes' stock was trading at $27.74 at the start of the year. Since then, ALKS shares have decreased by 11.3% and is now trading at $24.60. View the best growth stocks for 2024 here. Are investors shorting Alkermes? Alkermes saw a drop in short interest in the month of May. As of May 31st, there was short interest totaling 11,730,000 shares, a drop of 9.4% from the May 15th total of 12,940,000 shares. Based on an average daily volume of 1,890,000 shares, the short-interest ratio is presently 6.2 days. View Alkermes' Short Interest. When is Alkermes' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 24th 2024. View our ALKS earnings forecast. How were Alkermes' earnings last quarter? Alkermes plc (NASDAQ:ALKS) released its quarterly earnings data on Wednesday, May, 1st. The company reported $0.43 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.58 by $0.15. The business earned $350.37 million during the quarter, compared to analyst estimates of $360.26 million. Alkermes had a trailing twelve-month return on equity of 20.31% and a net margin of 25.17%. The business's revenue was up 21.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.10) EPS. What ETFs hold Alkermes' stock? ETFs with the largest weight of Alkermes (NASDAQ:ALKS) stock in their portfolio include Subversive Mental Health ETF (SANE), AdvisorShares Psychedelics ETF (PSIL), iShares Neuroscience and Healthcare ETF (IBRN), Invesco S&P SmallCap Health Care ETF (PSCH), Horizon Kinetics Medical ETF (MEDX), First Trust NYSE Arca Biotechnology Index Fund (FBT), ALPS Medical Breakthroughs ETF (SBIO) and Pacer US Small Cap Cash Cows 100 ETF (CALF). How will Alkermes' stock buyback program work? Alkermes announced that its Board of Directors has approved a share buyback plan on Thursday, February 15th 2024, which authorizes the company to buyback $400,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 8.2% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's board believes its shares are undervalued. What guidance has Alkermes issued on next quarter's earnings? Alkermes issued an update on its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided EPS guidance of 2.800-2.800 for the period, compared to the consensus earnings per share estimate of 2.740. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion. What is Richard F. Pops' approval rating as Alkermes' CEO? 119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees. What other stocks do shareholders of Alkermes own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA). Who are Alkermes' major shareholders? Alkermes' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.91%), Price T Rowe Associates Inc. MD (4.92%), Westfield Capital Management Co. LP (0.76%), Jacobs Levy Equity Management Inc. (0.74%), Jupiter Asset Management Ltd. (0.60%) and Principal Financial Group Inc. (0.58%). Insiders that own company stock include Blair Curtis Jackson, Cato T Laurencin, Christian Todd Nichols, Craig C Hopkinson, David Joseph Gaffin, Emily Peterson Alva, Michael J Landine, Nancy Wysenski, Richard F Pops and Shane Cooke. View institutional ownership trends. How do I buy shares of Alkermes? Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Alkermes have any subsidiaries? The following companies are subsidiares of Alkermes: Rodin Therapeutics.Read More This page (NASDAQ:ALKS) was last updated on 6/13/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredWall Street Icon: "I'd Put 50% of My Kids' Inheritance in THIS stock"Wall Street Icon Warns: "A Great Financial Reset is Underway" The man CNBC called "The Prophet" predicted t...Stansberry Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.